SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice regarding ARS Pharmaceuticals (SPRY), alleging securities fraud related to the commercialization timeline of neffy. The firm reminds investors of the class period from March 9, 2026 to June 24, 2026, with a lead plaintiff deadline of October 5, 2026.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.